Pharmacogenomics of Analgesics

  • Eugenia Ch. Yiannakopoulou


Pharmacogenomics investigates interindividual genetic variability in DNA sequence of drug targets, drug-metabolising enzymes or disease genes, RNA expression or protein translation of genes affecting drug response and drug safety. Variation exists in patient response on analgesic treatment in terms of efficacy and safety. This variation may be in part explained by pharmacogenomics. This chapter overviews data on pharmacogenomics of opioids and nonsteroidal anti-inflammatory agents focusing on the effect of genetic variation on efficacy and safety of analgesic agents. However, there is limited level I evidence on this topic. Most data come from case-control studies and case reports. Basic research should focus on the identification of biologically meaningful polymorphisms enabling a hypothesis with biological plausibility driven research in the field of pharmacogenomics of analgesics.


Opioid Receptor Poor Metabolisers Extensive Metabolisers A118G Polymorphism CYP2C8 Polymorphism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aithal GP, Day CP, Leathart JB, Daly AK (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511–518PubMedCrossRefGoogle Scholar
  2. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O (2012) Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol 68:55–64PubMedCentralPubMedCrossRefGoogle Scholar
  3. Blanco G, Martinez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG et al (2008) Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 18:37–43PubMedCrossRefGoogle Scholar
  4. Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C et al (2003) Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 42:283–292PubMedCrossRefGoogle Scholar
  5. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G (2009) Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 361:827–828PubMedCrossRefGoogle Scholar
  6. Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73–77PubMedGoogle Scholar
  7. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC (2012) Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321–326PubMedCentralPubMedCrossRefGoogle Scholar
  8. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281PubMedCrossRefGoogle Scholar
  9. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J (2008) UGT2B7 promoter variant −840G > A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83:200–202PubMedCrossRefGoogle Scholar
  10. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA (2004) Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol 58:71–80PubMedCentralPubMedCrossRefGoogle Scholar
  11. Duggan DE, Hogans AF, Kwan KC, McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181:563–575PubMedGoogle Scholar
  12. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M (1998) Same incidence of adverse events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27–33PubMedCrossRefGoogle Scholar
  13. Elkalioubie A, Allorge D, Robriquet L, Wiart JF, Garat A, Broly F, Fourrier F (2011) Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer. Eur J Clin Pharmacol 67:855–858PubMedCrossRefGoogle Scholar
  14. Evans W (1999) Translating functional genomics into rational therapeutics. Science 286:487–491PubMedCrossRefGoogle Scholar
  15. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72:76–89PubMedCrossRefGoogle Scholar
  16. Galley HF, Mahdy A, Lowes DA (2005) Pharmacogenetics and anesthesiologists. Pharmacogenomics 6:849–856PubMedCrossRefGoogle Scholar
  17. Gan SH, Ismail R, Wan Adnan WA, Zulmi W (2007) Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 11:171–181PubMedCrossRefGoogle Scholar
  18. García-Martín E, Martínez C, Tabares B, Frías J, Agúndez JA (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76:119–127PubMedCrossRefGoogle Scholar
  19. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831PubMedCrossRefGoogle Scholar
  20. Hamman MA, Thompson GA, Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33–41PubMedCrossRefGoogle Scholar
  21. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, Skorpen F (2002) Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353–356PubMedCrossRefGoogle Scholar
  22. Hutzler JM, Kolwankar D, Hummel MA, Tracy TS (2002) Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 30:1194–1200PubMedCrossRefGoogle Scholar
  23. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G (2012) More codeine fatalities after tonsillectomy in North American children. Pediatrics 129:e1343–e1347PubMedCrossRefGoogle Scholar
  24. Kirchheiner J, Seeringer A (2007) Clinical implications of pharmacogenetics of P450 drug metabolising enzymes. Biochim Biophys Acta 1770:489–494PubMedCrossRefGoogle Scholar
  25. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J (2003) Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 55:51–61PubMedCentralPubMedCrossRefGoogle Scholar
  26. Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmoller J (2004) The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 1:63–84CrossRefGoogle Scholar
  27. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J (2008) Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 28:78–83PubMedCrossRefGoogle Scholar
  28. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH et al (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969–978PubMedCrossRefGoogle Scholar
  29. Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, Kalso EA (2010) Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand J Pain 1:24–33CrossRefGoogle Scholar
  30. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ (2011) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. doi: 10.1111/j.1369-1600.2011.00349.x PubMedGoogle Scholar
  31. Madadi P, Koren G, Cairns J et al (2007) Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 53:33–35PubMedCentralPubMedGoogle Scholar
  32. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS et al (2009) Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 85(1):31–35PubMedCrossRefGoogle Scholar
  33. Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G (2010) Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 126:e986–e989PubMedCrossRefGoogle Scholar
  34. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG et al (2004) Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 141:205–208PubMedCentralPubMedCrossRefGoogle Scholar
  35. Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA (2005) The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 59:62–69PubMedCentralPubMedCrossRefGoogle Scholar
  36. Martínez C, Blanco G, García-Martín E, Agúndez JA (2006) Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs. Farm Hosp 30:240–248PubMedCrossRefGoogle Scholar
  37. Meyer UA (2000) Pharmacogenetics of adverse drug reactions. Lancet 356:1667–1671PubMedCrossRefGoogle Scholar
  38. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ (1996) Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 51:1003–1008PubMedCrossRefGoogle Scholar
  39. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlundudenaes M, Rane A (1995) Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolizers and one poor metabolizer of dextromethorphan. Br J Clin Pharmacol 39:182–186PubMedCentralPubMedCrossRefGoogle Scholar
  40. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E et al (2007) Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133:465–471PubMedCrossRefGoogle Scholar
  41. Pirmohamed M (2010) Pharmacogenetics of idiosyncratic adverse drug reactions. In: Uetrecht J (ed) Adverse drug reactions, Handbook of experimental pharmacology. Springer, Hielderberg, pp 478–491Google Scholar
  42. Poulsen L, Riishede L, Brosen K, Clemensen S, Sindrup SH (1998) Codeine in post-operative pain—study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur J Clin Pharmacol 54:451–454PubMedCrossRefGoogle Scholar
  43. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P (2010) Contribution of the different UDP-glucuro-nosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40–45PubMedCrossRefGoogle Scholar
  44. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160:907–918PubMedCentralPubMedCrossRefGoogle Scholar
  45. Siva C, Yokoyama WM, McLeod HL (2002) Pharmacogene-tics in rheumatology: the prospects and limitations of an emerging field. Rheumatology 41:1273–1279PubMedCrossRefGoogle Scholar
  46. Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F (2012) Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl LekListy 113:152–155Google Scholar
  47. Stamer UM, Kehnen K, Hothker F, Wolf S, Hoeft A (2003) Impact of CYP2D6 on postoperative tramadol analgesia. Pain 105:231–238PubMedCrossRefGoogle Scholar
  48. Stamer UM, Stüber F, Muders T, Musshoff F (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107:926–929PubMedCrossRefGoogle Scholar
  49. Tang W (2003) The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 4:319–329PubMedCrossRefGoogle Scholar
  50. Voronov P, Przybylo HJ, Jagannathan N (2007) Apnea in a child after oral codeine: a genetic variant – an ultra-rapid metabolizer. Paediatr Anaesth 17:684–687PubMedCrossRefGoogle Scholar
  51. Wang G, Zhang H, He F, Fang X (2006) Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 62:927–931PubMedCrossRefGoogle Scholar
  52. Weber WW (1999) Populations and genetic polymorphisms. Mol Diagn 4:299–307PubMedCrossRefGoogle Scholar
  53. Wilcox R, Owen H (2000) Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anesthetist. Anaesth Intensiv Care 28:611–619Google Scholar
  54. Williams DG, Patel A, Howard RF (2002) Pharmaco-genetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839–845PubMedCrossRefGoogle Scholar
  55. Wong SH, Wagner MA, Jentzen JM, Schur C, Bjerke J, Gock SB et al (2003) Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? J Forensic Sci 48:1406–1415PubMedGoogle Scholar
  56. Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjöqvist F et al (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57:729–735PubMedCrossRefGoogle Scholar
  57. Zarza J (2003) Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost 90:161–162PubMedGoogle Scholar
  58. Zhao J, Leemann T, Dayer P (1992) In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 51:575–581PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2013

Authors and Affiliations

  1. 1.Department of Basic Medical Lessons, Faculty of Health and Caring ProfessionsTechnological Educational Institute of AthensAthensGreece

Personalised recommendations